Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...

Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...

The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed- ...

XPeng's margins, pricing strategy, and competition with BYD spark cautious investment outlooks. Read an investment analysis ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.

Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with significant incentives for developing effective treatments for conditions ...

ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid a possible leak of encouraging clinical trial data. Analyst Prakhar ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...